Stereocomplex Coating for Implantable Device Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polymers used in implantable medical devices, such as drug-eluting stents, undergo physical aging due to residual and applied stresses, leading to reduced mechanical stability and variability in drug release rates, which affects the long-term efficacy and stability of these devices.
Innovation Solution
A stereocomplex coating of poly(D-lactic acid) (PDLA) and poly(L-lactic acid) (PLLA) is applied directly over the device body, comprising a primer layer with the stereocomplex, which can also form a reservoir or topcoat layer, enhancing mechanical stability and controlling drug release by forming a quasi-crystalline structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymers are used in implantable medical devices, then the devices can be manufactured with standard materials, but the polymers undergo physical aging due to residual and applied stresses, leading to reduced mechanical stability and variability in drug release rates
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional single-enantiomer polymers to stereocomplexes formed by complementary enantiomers (L-lactide and D-lactide). This fundamental material parameter change results in a quasi-crystalline structure with higher melting point and greater resistance to physical aging, thereby improving mechanical stability and extending device useful life without compromising manufacturability
Solution Approach 2:
The patent employs composite materials by combining two enantiomeric polymers (PDLA and PLLA) to form a stereocomplex coating system. This composite approach creates a multi-layer structure where the stereocomplex primer layer provides enhanced mechanical stability and the drug reservoir layer provides controlled drug release, resolving the contradiction between reliability and duration of action
2Ease of operation
If polymers are used to control drug release rates, then drug delivery can be controlled, but the polymers age by physical, chemical and/or electrical processes, rendering them unsuitable for their originally intended purpose
Solution Approach 1:
The patent changes the material parameter from conventional polymers to stereocomplexes with quasi-crystalline structure. This parameter change maintains the ability to control drug release rates through the reservoir layer composition while simultaneously improving long-term stability by resisting physical aging processes that would otherwise render the polymer unsuitable for its intended purpose
Solution Approach 2:
The patent segments the coating into distinct functional layers: a stereocomplex primer layer that provides mechanical stability and resistance to aging, and a separate drug reservoir layer that controls drug release. This segmentation allows each layer to optimize its specific function without compromising the other, resolving the contradiction between ease of operation and reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stereocomplex coating increases the thermal stability and mechanical properties of the device, reducing physical aging and providing consistent drug release rates, thereby extending the device's useful life and improving the controlled delivery of bioactive agents.
Implementation Method 1
a coating comprising a stereocomplex of poly(D-lactic acid) (PDLA) and poly(L-lactic acid) (PLLA) disposed over the device body... wherein the stereocomplex is included in the primer layer that is directly disposed over the device body
Data Source
AI summary
Implantable medical device coatings that have improved mechanical stability and medical devices coated with such coatings are disclosed.